Literature DB >> 17241511

Novel targets for anticancer treatment development in colorectal cancer.

Teresa Macarulla1, Francisco Javier Ramos, Jaume Capdevila, Cristina Saura, Josep Tabernero.   

Abstract

Despite recent advances in the treatment of metastatic colorectal cancer (CRC), the prognosis of patients with this malignancy remains poor. An emerging understanding of the molecular pathways that characterize cell growth, cell cycle, apoptosis, angiogenesis, and invasion has provided novel targets in cancer therapy. Numerous proteins have been implicated as having a crucial role in CRC. There are different targets according to their cellular localization such as membrane receptor targets, intracellular signaling targets, and other protein kinases that regulate cell division. Emerging data from the clinical development of new drugs directed to these targets are providing novel opportunities in the treatment of patients with CRC that will probably translate into an efficacy advantage in the years to come. In this article, we review the current developmental status of some of the most advanced targeted therapies in the treatment of CRC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17241511     DOI: 10.3816/CCC.2006.n.045

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  5 in total

1.  A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).

Authors:  José María Viéitez; Manuel Valladares; Ignacio Peláez; Luis de Sande González; Jesús García-Foncillas; José Luis García-López; Carlos García-Girón; Margarita Reboredo; Humberto Bovio; Angel Jiménez Lacave
Journal:  Invest New Drugs       Date:  2010-03-06       Impact factor: 3.850

2.  Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib.

Authors:  Rebecca A Dumont; Isabel Hildebrandt; Helen Su; Roland Haubner; Gerald Reischl; Johannes G Czernin; Paul S Mischel; Wolfgang A Weber
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

3.  A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment.

Authors:  Chi-Jung Huang; Shung-Haur Yang; Shih-Ming Huang; Chih-Ming Lin; Chih-Cheng Chien; Yan-Chu Chen; Chia-Long Lee; Hao-Han Wu; Chun-Chao Chang
Journal:  J Transl Med       Date:  2011-05-28       Impact factor: 5.531

4.  EGFR expression in gallbladder carcinoma in North America.

Authors:  Matthew Kaufman; Bhoomi Mehrotra; Sewanti Limaye; Sherrie White; Alexander Fuchs; Yehuda Lebowicz; Sandy Nissel-Horowitz; Adrienne Thomas
Journal:  Int J Med Sci       Date:  2008-09-22       Impact factor: 3.738

5.  Gamma-secretase inhibition combined with platinum compounds enhances cell death in a large subset of colorectal cancer cells.

Authors:  Tamara Aleksic; Stephan M Feller
Journal:  Cell Commun Signal       Date:  2008-10-24       Impact factor: 5.712

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.